Hepion Pharmaceuticals, Inc. (HEPA): Nasdaq/NYSE listing notice — Nasdaq deems Hepion a 'public shell' as additional delisting basis; hearing April 29

Hepion Pharmaceuticals, Inc.

Received Nasdaq notice on April 15, 2025, alleging company is a 'public shell' and continued listing unwarranted.
Nasdaq Hearings Panel will consider this matter at hearing scheduled for April 29, 2025.
Company intends to present its views on the additional deficiency at the Panel hearing.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Hepion Pharmaceuticals, Inc. received a nasdaq delisting notice notice regarding other.

Exchange: nasdaq
Notice: delisting notice

Exact text from the filing

April 15, 2025, Hepion Pharmaceuticals, Inc., a Delaware corporation (the “ Company ”), received written notice (the “ Notice ”) from the Nasdaq Stock Market, LLC (“ Nasdaq ”) indicating that the Staff believes that the Company is a “public shell” and that the continued listing of its securities is no longer warranted. The Staff stated that this serves as an additional basis for delisting the Company’s securities from The Nasdaq Stock Market. The Notice is formal notification that the Nasdaq Hearings Panel (the “Panel”) will consider this matter in rendering a determination regarding the Compa

View on SEC.gov

93 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Hepion Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001641172-25-005241

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.